Abstract
The biologic activity of individual cancer cells is highly heterogeneous. Hypoxia, one of the prominent features of a tumor microenvironment, is thought to be causal in generating this cellular heterogeneity. In this study, we revealed that primary lung cancer cells harboring activating epidermal growth factor receptor (EGFR) mutations generally entered a dormant state when hypoxic. We found that heterodimer formation of the ERBB family receptor tyrosine kinases (RTKs), and their subsequent downstream signaling, was diminished under hypoxic conditions, although phosphorylation of the EGFR was retained. Dormant lung cancer cells were found to be resistant to EGFR tyrosine kinase inhibitor (TKI) treatment. In terms of mechanism, we found that a negative regulator of ERBB signaling, MIG6/ERRFI1/RALT/Gene33, was induced by hypoxia both in vitro and in vivo. MIG6 expression prevented heterodimer formation of ERBB family RTKs, and suppressed their downstream signaling. Knockdown of MIG6 enhanced tumor cell growth under hypoxic conditions, and promoted the phosphorylation of ERK and AKT via increased EGFR-HER3 binding. Critically, sensitivity to an EGFR-TKI, as well as to irradiation under hypoxic conditions, was increased in MIG6 knockdown cells. The expression of MIG6 was partly correlated with a pS6 negative zone in patient tumors. Analyses of tumor sections from 68 patients with activating EGFR mutations showed that patients with high MIG6 expression showed significantly shorter survival after EGFR-TKI treatment than other groups. Collectively, our data suggest that dormant cancer cells with a high MIG6 expression level might be one of the causes of EGFR-TKI resistance in EGFR mutant lung cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marusyk A, Almendro V, Polyak K . Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323–334.
Gilkes DM, Semenza GL, Wirtz D . Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 2014; 14: 430–439.
Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012; 3: 783.
Semenza GL . The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta 2016; 1863: 382–391.
Sosa MS, Bragado P, Aguirre-Ghiso JA . Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014; 14: 611–622.
Endo H, Okuyama H, Ohue M, Inoue M . Dormancy of cancer cells with suppression of AKT activity contributes to survival in chronic hypoxia. PLoS One 2014; 9: e98858.
Lowe SW, Cepero E, Evan G . Intrinsic tumour suppression. Nature 2004; 432: 307–315.
Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
Arsham AM, Howell JJ, Simon MC . A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278: 29655–29660.
Endo H, Murata K, Mukai M, Ishikawa O, Inoue M . Activation of insulin-like growth factor signaling induces apoptotic cell death under prolonged hypoxia by enhancing endoplasmic reticulum stress response. Cancer Res 2007; 67: 8095–8103.
Okuyama H, Endo H, Akashika T, Kato K, Inoue M . Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010; 70: 10213–10223.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.
Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H, Tsujii M et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci USA 2011; 108: 6235–6240.
Endo H, Okami J, Okuyama H, Kumagai T, Uchida J, Kondo J et al. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol 2013; 8: 131–139.
Ruvinsky I, Meyuhas O . Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006; 31: 342–348.
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y . Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 1996; 271: 19029–19032.
Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J . Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007; 450: 741–744.
Swinson DEB . Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003; 21: 473–482.
Silvera D, Formenti SC, Schneider RJ . Translational control in cancer. Nat Rev Cancer 2010; 10: 254–266.
Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28: 501–512.
Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob MD, Fabian MR et al. An oxygen-regulated switch in the protein synthesis machinery. Nature 2012; 486: 126–129.
Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC . Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 2008; 283: 16309–16319.
Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K et al. The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 2014; 74: 3995–4005.
Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B et al. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 2007; 26: 269–276.
Lafont JE, Talma S, Hopfgarten C, Murphy CL . Hypoxia promotes the differentiated human articular chondrocyte phenotype through SOX9-dependent and -independent pathways. J Biol Chem 2008; 283: 4778–4786.
Barker HE, Paget JT, Khan AA, Harrington KJ . The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 2015; 15: 409–425.
Crea F, Nur Saidy NR, Collins CC, Wang Y . The epigenetic/noncoding origin of tumor dormancy. Trends Mol Med 2015; 21: 206–211.
Amin R, Morita-Fujimura Y, Tawarayama H, Semba K, Chiba N, Fukumoto M et al. DeltaNp63alpha induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines. Mol Oncol 2016; 10: 575–593.
Peart T, Ramos Valdes Y, Correa RJ, Fazio E, Bertrand M, McGee J et al. Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids. Oncotarget 2015; 6: 22424–22438.
Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M et al. Mitotic quiescence, but not unique 'stemness,' marks the phenotype of bone metastasis-initiating cells in prostate cancer. FASEB J 2015; 29: 3141–3150.
Bui AT, Laurent F, Havard M, Dautry F, Tchenio T . SMAD signaling and redox imbalance cooperate to induce prostate cancer cell dormancy. Cell Cycle 2015; 14: 1218–1231.
Tiram G, Segal E, Krivitsky A, Shreberk-Hassidim R, Ferber S, Ofek P et al. Identification of dormancy-associated microRNAs for the design of osteosarcoma-targeted dendritic polyglycerol nanopolyplexes. ACS Nano 2016; 10: 2028–2045.
Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P et al. NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven quiescence programmes. Nat Commun 2015; 6: 6170.
Ameri K, Jahangiri A, Rajah AM, Tormos KV, Nagarajan R, Pekmezci M et al. HIGD1A regulates oxygen consumption, ROS production, and AMPK activity during glucose deprivation to modulate cell survival and tumor growth. Cell Rep 2015, pii S2211–1247.
Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK . Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 2004; 64: 7336–7345.
Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ et al. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest 2015; 125: 2484–2496.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–1043.
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479–9487.
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 2012; 109: E2127–E2133.
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2: 922–933.
Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009; 15: 6630–6638.
Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A et al. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 2012; 103: 1946–1954.
Makkinje A, Quinn DA, Chen A, Cadilla CL, Force T, Bonventre JV et al. Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 2000; 275: 17838–17847.
Xu D, Patten RD, Force T, Kyriakis JM . Gene 33/RALT is induced by hypoxia in cardiomyocytes, where it promotes cell death by suppressing phosphatidylinositol 3-kinase and extracellular signal-regulated kinase survival signaling. Mol Cell Biol 2006; 26: 5043–5054.
Anastasi S, Lamberti D, Alema S, Segatto O . Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Semin Cell Dev Biol 2016; 50: 115–124.
Carroll VA, Ashcroft M . Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264–6270.
Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 2006; 12: 568–573.
Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R et al. Loss of MIG6 accelerates initiation and progression of mutant epidermal growth factor receptor-driven lung adenocarcinoma. Cancer Discov 2015; 5: 534–549.
Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S et al. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS One 2013; 8: e68966.
Sato Y, Tateno H, Adachi J, Okuyama H, Endo H, Tomonaga T et al. Generation of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen. Sci Rep 2016; 6: 24823.
Nakajima A, Endo H, Okuyama H, Kiyohara Y, Kimura T, Kamiura S et al. Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix. Int J Cancer 2015; 136: 2949–2960.
Acknowledgements
We thank Dr T Tabuchi and Dr K Fukui for statistical counseling, N Kanto and T Yasuda for technical assistance, and M Izutsu for secretarial assistance. This work was supported by JSPS Grant-in-Aid for Scientific Research on Innovative Areas (26111005) (to MI) and KAKENHI (25461937) (to HE).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Endo, H., Okami, J., Okuyama, H. et al. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations. Oncogene 36, 2824–2834 (2017). https://doi.org/10.1038/onc.2016.431
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2016.431
This article is cited by
-
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer
Oncogene (2023)
-
Involvement of redox signalling in tumour cell dormancy and metastasis
Cancer and Metastasis Reviews (2023)
-
Transcriptional landscape of cellular networks reveal interactions driving the dormancy mechanisms in cancer
Scientific Reports (2021)
-
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
BMC Cancer (2020)
-
Cancer progression and the invisible phase of metastatic colonization
Nature Reviews Cancer (2020)